The Drug-Induced Respiratory Disease Website and App

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

X. Systemic/Distant conditions, syndromes and reactions

X.y Subclinical ANA positivity

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.am Hemilingual (angio)edema

XV. Pathology

XV.al Path: Pulmonary hypertension incl. angiomatoid vasculopathy

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.s A mass or masses

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (a.k.a. Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.at Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.l Postoperative ARDS

IV. Airway involvement

IV.r Airway pigmentation (black, bluish, petechial)

V. Pleural and/or pericardial involvement

V.t The apical cap

VI. Pulmonary vasculopathy

VI.i Acute pulmonary hypertension

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.f Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.n Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.au Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also pattern If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.j Path: Pulmonary fibrosis (UIP-pattern)

XV. Pathology

XV.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XV. Pathology

XV.m Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.r Path: Smudged geographic necrosis

XV. Pathology

XV.ao Path: Pleuritis, pleural fibrosis

XV. Pathology

XV.bt Path: Histiocytic proliferation

XV. Pathology

XV.dc Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.aa Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ay Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.az Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bj Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bq Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bt Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.bx Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ca Imaging: Disseminated patchy pulmonary opacities

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.p Eye-catcher: An electron-dense ('white') thyroid

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.e BAL: Stainable iron in macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.m BAL: A normal cell differential

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.p BAL: Lamellar bodies in AM on EM

XXVIII. Pulmonary physiology - PFTs

XXVIII.c Platypnea-orthodeoxia

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.g Cough syncope

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.q Tongue involvement (edema, glossitis, hematoma)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.y Sinonasal discharge, -blockage, -obstruction

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.e Disordered breathing pattern incl. Cheyne-Stokes respiration

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.q Obstructive sleep apnea

X. Systemic/Distant conditions, syndromes and reactions

X.au Visceral angioedema (can cause relapsing abdominal pain)

XIII. Neoplastic conditions

XIII.a Lung cancer

XVI. Imaging

XVI.bu Imaging: Upper/central airway narrowing

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.f Eye-catcher: Tongue edema

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.m Coagulopathy

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.e Pulmonary hematoma

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.k Epistaxis

IV. Airway involvement

IV.af Calcification of tracheobronchial cartilaginous rings

VII. Mediastinal involvement

VII.g Hemomediastinum - Mediastinal hematoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.b Hematoma of/around central airway wall potentially causing UAO

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.u Vocal cord hematoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.v Retropharyngeal hematoma (may cause UAO)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.x Thoracic epidural or spinal hematoma

XI. Miscellaneous

XI.k Esophageal hematoma (may cause chest pain and/or tracheal compression)

XI. Miscellaneous

XI.am Rectus abdominis hematoma

XII. Cardiovascular involvement / toxicity

XII.ar Calcification of the coronary artery walls or atheroma

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.d BAL: Gross or microscopic bleeding/hemorrhage

XXIV. Veterinary medicine

XXIV.e Veterinary: Tracheal hemorrhage, stenosis, collapse

II. Pulmonary edema - Acute lung injury - ARDS

II.e Transfusion-related acute lung injury (TRALI) (May cause ARDS)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.u Pulmonary vascular microthrombi

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

VII. Mediastinal involvement

VII.b Lymphadenopathy with reactive changes

X. Systemic/Distant conditions, syndromes and reactions

X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.as Pharmacobezoar

XI. Miscellaneous

XI.az Sneezing (may cause pulmonary barotrauma)

XV. Pathology

XV.w Path: Pulmonary edema (see also II/IIa)

I. Interstitial/parenchymal lung disease

I.ao Pulmonary infiltrates

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

IV. Airway involvement

IV.z Bronchial wall erosion/hematoma

IV. Airway involvement

IV.ah Bronchopericardial fistula

V. Pleural and/or pericardial involvement

V.n Hemopericardium - Bloody pericardial effusion

VI. Pulmonary vasculopathy

VI.o Air/gas embolism

VI. Pulmonary vasculopathy

VI.z Pulmonary vein stenosis

VI. Pulmonary vasculopathy

VI.ac Pulmonary infarction

VI. Pulmonary vasculopathy

VI.ae Pulmonary vein perforation/rupture

VII. Mediastinal involvement

VII.d Fibrosing mediastinitis

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.h Vocal cord dysfunction, adduction, closure, injury

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.j Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.n Vagal nerve injury (may cause GE reflux/GERD)

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.y Pneumopericardium

XII. Cardiovascular involvement / toxicity

XII.aw Postcardiac/-cardiotomy injury (PCIS-Dressler syndrome)

XII. Cardiovascular involvement / toxicity

XII.bd Perforation of the heart - Cardiac rupture

XII. Cardiovascular involvement / toxicity

XII.bg Atrio-esophageal fistula

XII. Cardiovascular involvement / toxicity

XII.bh Atrial septal defect, acquired

XII. Cardiovascular involvement / toxicity

XII.bk Pulmonary vein thrombosis

XII. Cardiovascular involvement / toxicity

XII.cb Pericardial-esophageal fistula

XV. Pathology

XV.ah Path: Pulmonary congestion

XV. Pathology

XV.ak Path: Pulmonary veno-occlusive disease (PVOD)

XV. Pathology

XV.cx Path: Pulmonary vein stenosis

XVI. Imaging

XVI.l Imaging: Peribronchovascular areas of consolidation

XVI. Imaging

XVI.bg Imaging: Pulmonary vein stenosis

XVI. Imaging

XVI.bo Imaging: Localized calcification of pulmonary vein or veins

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XXVII. Esophageal involvement

XXVII.a Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP) (secondary)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.c Pleural thickening - Fibrothorax

V. Pleural and/or pericardial involvement

V.h Chylothorax

V. Pleural and/or pericardial involvement

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

X. Systemic/Distant conditions, syndromes and reactions

X.r Fluid retention

XV. Pathology

XV.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

XV. Pathology

XV.ch Path: Organizing fibrinous pleuritis (OFP)

XVI. Imaging

XVI.m Imaging: Interlobular septal thickening

XVI. Imaging

XVI.an Imaging: Pleural effusion

II. Pulmonary edema - Acute lung injury - ARDS

II.g Negative pressure pulmonary edema (NPPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.ap Halitosis - Breath malodor

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.m Cardiac- cardiorespiratory/pulmonary arrest

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.cd ST segment changes

XV. Pathology

XV.z Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ad Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.aj Shrinking lung syndrome

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

IV. Airway involvement

IV.c Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.y Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.ab Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.s Serositis - Polyserositis

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.t Vocal cord paresis/paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.n Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.am Immune-related adverse effect/toxicity

X. Systemic/Distant conditions, syndromes and reactions

X.an Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.aw Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ay Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bi Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.n Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.y Adrenal suppression

XI. Miscellaneous

XI.ag Vertebral compression fracture

XI. Miscellaneous

XI.au Graft vs. host disease in transplant recipients

XI. Miscellaneous

XI.av Deterioration of graft function in SOT recipients

XI. Miscellaneous

XI.ba Nonrespiratory AE of interest

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.r Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.s Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.ax Necrotizing myocarditis (w/o evidence for CAD)

XII. Cardiovascular involvement / toxicity

XII.ba Sudden cardiac death

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.l Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XV. Pathology

XV.v Path: Micronodular organizing pneumonia/BOOP

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.ca Path: Myocarditis

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XV. Pathology

XV.cp Path: Pneumocyte vacuolization

XV. Pathology

XV.cw Path: Myocardial vasculitis

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.bh Imaging: F18-PET scan positive lympadenopathy

XVI. Imaging

XVI.bm Imaging: Avid pleural uptake on PET-scan

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.q Viral pneumonia

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes